Consun Pharmaceutical Group Limited (HKG:1681)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
16.28
-0.72 (-4.24%)
At close: Mar 6, 2026
Market Cap13.70B +104.5%
Revenue (ttm)3.58B +19.3%
Net Income1.11B +20.6%
EPS1.29 +14.0%
Shares Out841.32M
PE Ratio12.62
Forward PE10.32
Dividend0.66 (4.05%)
Ex-Dividend Daten/a
Volume2,626,742
Average Volume1,466,267
Open17.10
Previous Close17.00
Day's Range16.28 - 17.19
52-Week Range7.61 - 19.49
Beta0.57
RSI38.01
Earnings DateMar 26, 2026

About HKG:1681

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass... [Read more]

Sector Healthcare
Founded 1997
Employees 3,073
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1681
Full Company Profile

Financial Performance

In 2024, HKG:1681's revenue was 2.97 billion, an increase of 14.56% compared to the previous year's 2.59 billion. Earnings were 910.46 million, an increase of 16.05%.

Financial numbers in CNY Financial Statements